<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Guidelines for the prevention and management of &lt;em&gt;Mycobacterium tuberculosis&lt;/em&gt; infection and disease in adult patients with chronic kidney disease.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, Khoo S, Ormerod P, Ostermann M, Snelson C. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010 Jun;65(6):559-70. [113 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20522863&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic kidney disease, unspecified  (585.9); End stage renal disease  (585.6); General physical examination  (89.7); Hemodialysis  (39.95); Peritoneal dialysis  (54.98); Primary tuberculous infection, unspecified, unspecified  (010.90)"/><FieldValue Value="MSH: Chemoprevention ; Drug Therapy ; Interferon-gamma Release Tests ; Interprofessional Relations ; Isoniazid ; Kidney Failure, Chronic ; Kidney Transplantation ; Latent Tuberculosis ; Mandatory Reporting ; Medical History Taking ; Medication Therapy Management ; Microbial Sensitivity Tests ; Patient Isolation ; Peritoneal Dialysis ; Physical Examination ; Pyridoxine ; Referral and Consultation ; Rifampin ; Risk Assessment ; Tuberculin Test ; Tuberculosis "/><FieldValue Value="MTH: Chemoprevention ; Chronic Kidney Diseases ; Hemodialysis ; isoniazid ; Kidney Failure, Chronic ; Kidney Transplantation ; Microbial Sensitivity Tests ; Patient Monitoring ; Peritoneal Dialysis ; Pharmacotherapy ; physical examination ; Plain chest X-ray ; pyridoxine ; Rifampin ; Risk Assessment ; Tuberculin Test ; Tuberculosis "/><FieldValue Value="PDQ: isoniazid ; kidney transplantation ; rifampin "/><FieldValue Value="SNOMEDCT_US: Delayed hypersensitivity skin test for tuberculin PPD  (424294008); Drug therapy  (416608005); End stage renal disease  (46177005); End stage renal disease  (90688005); Hemodialysis  (302497006); Inactive tuberculosis  (11999007); Isolation nursing in negative pressure isolation environment  (444908001); Isoniazid  (387472004); Isoniazid  (81335000); Monitoring of patient  (182777000); Patient isolation chamber  (462180004); Peritoneal dialysis  (71192002); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Plain chest X-ray  (399208008); Prophylactic chemotherapy  (268500004); Pyridoxine  (36944009); Pyridoxine  (430469009); Rifampin  (29175007); Rifampin  (387159009); Risk assessment  (225338004); Transplant of kidney  (70536003); Tuberculosis  (371569005); Tuberculosis  (373576009); Tuberculosis  (56717001)"/><FieldValue Value="SPN: CHAMBER, PATIENT ISOLATION "/><FieldValue Value="UMD: Chambers, Isolation  (12-200); Hemodialysis Units, Renal  (24-896); Peritoneal Dialysis Units  (11-226); Radiographic Systems  (18-429); Radiographic Systems, Digital, Chest  (18-431)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Mycobacterium tuberculosis&lt;/em&gt; infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic kidney disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Infectious Diseases" /><FieldValue Value="Nephrology" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To quantify the risks of developing active disease and to give advice where possible on the management of tuberculosis (TB) infection and disease in patients (1) with all stages of chronic kidney disease (CKD); (2) on peritoneal dialysis and haemodialysis; and (3) with renal transplants &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To describe the risks of developing disease and the risks and benefits of treatment for latent TB infection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with all stages of chronic kidney disease (CKD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on peritoneal dialysis and haemodialysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with renal transplants &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with latent tuberculosis (TB) infection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Assessment/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient history of prior tuberculosis (TB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interferon gamma release assay (IGRA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tuberculin skin test &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Management of latent TB&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Monitoring and referral to specialist &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chemoprophylaxis (isoniazid, rifampicin, pyridoxine) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of active TB&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Sensitivity testing &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patient isolation (preferably in negative pressure facility) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Close cooperation between renal physicians and TB specialist &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Notification of authorities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Standard chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chemoprophylaxis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring of peak and trough drug levels &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dosing intervals &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of specific patient populations (haemodialysis, not on dialysis, renal transplantation) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Incidence of tuberculosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The initial systematic literature search (Medline, DataStar Web) was carried out by two members of the committee using tuberculosis, renal/kidney failure, renal transplant 1970-2009 as search criteria. A paper-based exploration of the relevant literature was pursued from this core dataset. Only English language papers including all well formulated clinical case series were included. Abstracts were excluded.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case-control or cohort studies &lt;em&gt;or&lt;/em&gt; High quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies, for example, case reports, case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The primary source literature has been individually graded for its methodology (where appropriate) and the grading given alongside the reference using the revised Scottish Intercollegiate Guidelines Network (SIGN)&amp;nbsp;levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;After the appraisal of data, the guideline was initially drafted, then discussed by the whole group, the evidence debated and redrafted several times. The draft was based where possible on any published evidence, but this was combined with clinical expertise where necessary and where no evidence was available.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Grades of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Grades of Recommendation&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Type of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta-analysis, systematic review or randomised controlled trial (RCT) rated as 1++ and directly applicable to the target population &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 1++ or 1+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2++&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence level 3 or 4 &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The manuscript was placed on the British Thoracic Society (BTS) website for consultation by the membership. Following this, further amendments were made and the document reviewed by the TB Specialist Advisory Group, Joint Tuberculosis and Standard of Care Committees of the BTS. After final approval from these committees together with input from the Renal Association, the guidelines were submitted for peer review prior to publication.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grade of the recommendation (&lt;strong&gt;A-D&lt;/strong&gt;) and the level of evidence (&lt;strong&gt;1++, 1+, 1-, 2++, 2+, 2-, 3, 4&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendations for Management of Latent Tuberculosis Infection (LTBI)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;All patients with chronic kidney disease (CKD) considered at risk for tuberculosis (TB) should have any history of prior TB or TB contact sought, any history of prior TB treatment checked (including drugs taken and treatment duration), a clinical examination, a chest x-ray and, if appropriate, an interferon gamma release assay (IGRA) test. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Any patient with CKD with an abnormal chest x-ray consistent with past TB, or a previous history of extrapulmonary TB but who has previously received adequate treatment should be monitored regularly and considered for referral to and assessment by a specialist with an interest in TB, either a thoracic or infectious disease physician. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine assessment of patients with CKD or those on haemodialysis or peritoneal dialysis with a tuberculin skin test (TST) or IGRA test is not recommended. Renal physicians may wish to assess individual patients at high risk of latent tuberculosis infection with an IGRA test (with or without a TST, a negative test being unhelpful) and discuss the results with a chest/infectious disease specialist in TB. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on the waiting list for renal transplantation may be assessed with an IGRA test (with or without a TST as above), giving the opportunity for chemoprophylaxis before transplantation. An individual risk assessment can be made using Tables 1-3 in the original guideline document. In general, all black African and Asian patients born outside the United Kingdom (UK) should be screened and considered for chemoprophylaxis prior to or after transplantation. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Chemoprophylaxis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;The decision on chemoprophylaxis regimen should be made by the thoracic or infectious disease physician after discussion with both the patient and renal team. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In general, isoniazid and rifampicin can be used in normal doses in renal impairment, during dialysis and following transplantation (see below). (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For chemoprophylaxis use 6 months of isoniazid 300 mg daily plus pyridoxine 10-25 mg daily, or isoniazid plus rifampicin (as Rifinah) plus pyridoxine for 3 months or rifampicin alone for 4-6 months. Any of these regimens is adequate for chemoprophylaxis. Long-term use of isoniazid is not recommended. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is no evidence to support chemoprophylaxis regimens of longer than 6 months for isoniazid alone, 3 months for isoniazid plus rifampicin, or 4-6 months for rifampicin alone. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is no evidence to support use of lower doses. These are inadequate for treatment of latent tuberculosis infection and lead to lower peak levels and possible development of drug resistance. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If patients who have had chemoprophylaxis develop symptoms suggestive of clinical TB, they should be promptly and appropriately investigated. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendations for the Management and Treatment of Active TB&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;11&quot;&gt;&#xD;&#xA;    &lt;li&gt;If active TB is suspected, every effort should be made to isolate an organism for sensitivity testing. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with active pulmonary disease should be isolated, preferably in negative pressure facilities. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All cases of TB should be notified to the proper officer, usually the local consultant in Communicable Disease Control. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Close cooperation between renal physicians and specialists in the management of TB is strongly recommended. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Active TB should be excluded in patients with CKD by appropriate investigations in patients who have an abnormal chest x-ray or a history of prior pulmonary or extrapulmonary TB that has been either inadequately or not previously treated. Chemoprophylaxis should be given. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TB should be considered in all patients with unexplained systemic or system-specific symptoms as extrapulmonary TB is common, particularly in patients on dialysis, with peritoneal TB being common in patients on chronic ambulatory peritoneal dialysis. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Any patient with active TB, either pulmonary or nonpulmonary, should receive standard chemotherapy agents, albeit with dose interval modifications where appropriate (see text in original guideline document for further details and for standard duration as per National Institute for Clinical Excellence [NICE] guidelines). (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Peak and trough drug levels should be monitored, particularly for ethambutol and the aminoglycosides, especially if there is concern regarding over- and under-dosing. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patients with CKD Not on Dialysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;19&quot;&gt;&#xD;&#xA;    &lt;li&gt;For patients with stages 4 and 5 CKD, &lt;em&gt;dosing intervals&lt;/em&gt; should be increased to three times weekly for ethambutol, pyrazinamide and the aminoglycosides. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Haemodialysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;20&quot;&gt;&#xD;&#xA;    &lt;li&gt;For patients on haemodialysis, &lt;em&gt;dosing intervals&lt;/em&gt; should be increased to three times weekly to reduce the risk of drug accumulation and toxicity. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment can be given immediately after haemodialysis to avoid premature drug removal. With this strategy there is a possible risk of raised drug levels of ethambutol and pyrazinamide between dialysis sessions. Alternatively, treatment can be given 4-6 h before dialysis, increasing the possibility of premature drug removal but reducing possible ethambutol or pyrazinamide toxicity. The choice of strategy may be influenced by a need to ensure adherence (when post dialysis offers the opportunity for directly observed therapy), practical issues (post dialysis for morning shift patients) and expected pharmacokinetics or drug interactions. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Renal Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;22&quot;&gt;&#xD;&#xA;    &lt;li&gt;Rifampicin in particular can interact with immunosuppressive regimens, increasing the chance of graft rejection, and doses of mycophenolate mofetil, tacrolimus and ciclosporin may need adjustment. Corticosteroid doses should be doubled in patients receiving rifampicin. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Grades of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Grades of Recommendation&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Type of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta-analysis, systematic review or randomised controlled trial (RCT) rated as 1++ and directly applicable to the target population &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 1++ or 1+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2++&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence level 3 or 4 &lt;em&gt;or&lt;/em&gt; &lt;br /&gt;&#xD;&#xA;            Extrapolated evidence from studies rated as 2+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Revised Scottish Intercollegiate Guidelines Network (SIGN) Grading System: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case-control or cohort studies &lt;em&gt;or&lt;/em&gt; High quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies, for example, case reports, case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Effective prevention and treatment of tuberculosis in patients with chronic kidney disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drug-induced hepatitis from various tuberculosis (TB) chemoprophylaxis regimens&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Isoniazid&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There have been case reports of neuropsychiatric problems in some chronic kidney disease (CKD) patients receiving isoniazid.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;There was an unusually high incidence (37%; 6 patients) of neuropsychiatric disturbance, with three cases of encephalopathy, in one series of 16 patients with tuberculosis (TB) receiving dialysis (reported in 2002). Other side effects occurred in patients with chronic kidney disease (CKD) and TB, but neuropsychiatric symptoms occurred exclusively in patients on dialysis. Symptoms usually developed within the first few weeks of treatment and included grand mal seizures (with no prior history), depressive psychosis, confusion, nightmares, hallucinations, peripheral neuropathy, twitching and dizziness. Encephalopathy was also reported in 3 of 48 dialysis patients with TB, and neuropsychiatric side effects due to isoniazid have been reported elsewhere in the literature as case reports. A quarter of those receiving dialysis also experienced significant gastrointestinal adverse effects (jaundice, nausea and vomiting). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ototoxicity has been described over a 10-year period in seven patients with CKD receiving isoniazid together with other drugs but not aminoglycosides. In two patients this reversed upon withdrawal of isoniazid. Rarely, renal failure itself may be associated with hearing loss due to the underlying disease (e.g., Alport syndrome, Wegener's granulomatosis) and by a variety of mechanisms such as axonal uraemic neuropathy and the increased susceptibility to ototoxins. Pharmacokinetic studies of isoniazid in renal failure, however, suggest that even though the half-life of isoniazid is increased by about 45% in slow acetylators, this does not lead to significant adverse events necessitating dosage reduction, and therapeutic drug monitoring is not thought to be necessary. Furthermore, there is evidence to suggest that administering isoniazid in reduced doses may lead to reduced potency and risk the development of resistance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pyridoxine supplementation should be given with isoniazid to prevent the development of peripheral neuropathy. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rifampicin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reported side effects for rifampicin do not appear to occur with significantly increased frequency in patients with CKD or on dialysis, although rifampicin has been cited as a rare cause of acute renal failure. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rifampicin in particular can interact with immunosuppressive regimens, increasing the chance of graft rejection, and doses of mycophenolate mofetil, tacrolimus and ciclosporin may need adjustment. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pyrazinamide&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Owing to pyrazinamide's effect on uric acid retention, this may lead to hyperuricaemia and gout.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ethambutol&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ethambutol is renally excreted and ocular toxicity is largely dose-dependent.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Aminoglycosides&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Streptomycin causes significant vestibular toxicity but less nephrotoxicity compared with the other aminoglycosides.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Azathioprine&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Azathioprine sometimes causes hepatotoxicity, which has to be differentiated from the hepatotoxicity due to antituberculosis drugs.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, Khoo S, Ormerod P, Ostermann M, Snelson C. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010 Jun;65(6):559-70. [113 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20522863&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Jun" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="British Thoracic Society - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Thoracic Society&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Group Members&lt;/em&gt;: Heather Milburn, Chest Clinic, Guy's and St Thomas' NHS Foundation Trust, London UK; Neil Ashman, Barts' and the London Renal Centre, London, UK; Peter Davies, Liverpool NHS Trust, Liverpool, UK; Sarah Doffman, Brighton General Hospital, Brighton, UK; Francis Drobniewski, Barts' and the London, London, UK; Saye Khoo, University of Liverpool, Liverpool, UK; Peter Ormerod, Royal Blackburn Hospital, Blackburn, UK; Marlies Ostermann, Guy's Hospital, London, UK; Catherine Snelson, Princess Royal Hospital, Telford, Birmingham, UK&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All members of the Guidelines Committee were asked to submit a written record of possible conflicts of interest to the Standards of Care Committee of the British Thoracic Society (BTS). PD has acted as an advisor for Oxford Immunotec (UK) and has received an honorarium. No other conflicts of interest were declared.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/tuberculosis-in-patients-with-chronic-kidney-disease/&quot; title=&quot;British Thoracic Society Web site&quot;&gt;British Thoracic Society Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Suggested audit criteria are available in the &lt;a href=&quot;https://www.brit-thoracic.org.uk/document-library/clinical-information/tuberculosis/tb-guidelines/guidelines-for-the-prevention-and-management-of-mycobacterium-tuberculosis-infection-and-disease-in-adult-patients-with-chronic-kidney-disease/&quot; title=&quot;BTS Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on August 17, 2012. The information was verified by the guideline developer on September 18, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
